Kerlone

Betaxolol Hydrochloride, the active ingredient in Kerlone, is a beta blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure and to relieve chest pain associated with angina pectoris in adult patients.

GNH USA supplies Kerlone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution, ensuring product integrity from manufacturing to end‑user delivery.

Betaxolol Hydrochloride acts on the cardiovascular system to control blood pressure and heart workload. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Angina pectoris: decreases myocardial oxygen demand, alleviating chest pain during exertion. - Ischemic heart disease: improves exercise tolerance by lowering heart rate and contractility.

Betaxolol Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: feeling of tiredness or reduced energy. - Dizziness: light‑headed sensation, especially upon standing. - Cold extremities: reduced blood flow to hands and feet. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Heart block: impairment of electrical conduction in the heart. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Betaxolol Hydrochloride, clinicians should consider several precautionary measures to ensure patient safety. - Monitor blood pressure: check regularly to assess therapeutic response. - Assess heart rate: watch for excessive bradycardia, especially in patients with conduction disorders. - Use cautiously in asthma: β1 selectivity reduces but does not eliminate risk of bronchospasm. - Adjust dose in renal impairment: reduced clearance may increase drug exposure. - Avoid abrupt discontinuation: tapering may prevent rebound hypertension. - Store below 25°C: keep in the original packaging, protect from moisture.

Betaxolol Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and hypotension. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): increased risk of heart block. - Antiarrhythmic agents (class I and III): may potentiate cardiac conduction disturbances.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect. - Diuretics: can enhance hypotensive response. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase betaxolol plasma levels. - Antidiabetic drugs: beta‑blockers may mask hypoglycemia symptoms.